{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:01:40Z","timestamp":1790128900849,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01-DK121970"],"award-info":[{"award-number":["R01-DK121970"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R61HD099995"],"award-info":[{"award-number":["R61HD099995"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00204-022-03369-0","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T05:03:01Z","timestamp":1662699781000},"page":"3219-3231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Study of the roles of cytochrome P450 (CYPs) in the metabolism and cytotoxicity of perhexiline"],"prefix":"10.1007","volume":"96","author":[{"given":"Zhen","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0402-4152","authenticated-orcid":false,"given":"Lei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"issue":"1","key":"3369_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/00498258609043506","volume":"16","author":"AGB Amoah","year":"1986","unstructured":"Amoah AGB, Gould BJ, Parke DV, Lockhart JDF (1986) Further studies on the pharmacokinetics of perhexiline maleate in humans. Xenobiotica 16(1):63\u201368","journal-title":"Xenobiotica"},{"issue":"1","key":"3369_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1527-3466.2007.00006.x","volume":"25","author":"H Ashrafian","year":"2007","unstructured":"Ashrafian H, Horowitz JD, Frenneaux MP (2007) Perhexiline. Cardiovasc Drug Rev 25(1):76\u201397","journal-title":"Cardiovasc Drug Rev"},{"issue":"2","key":"3369_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/toxsci\/kft254","volume":"137","author":"S Chen","year":"2014","unstructured":"Chen S, Xuan J, Wan L, Lin H, Couch L, Mei N, Dobrovolsky VN, Guo L (2014) Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci 137(2):404\u2013415","journal-title":"Toxicol Sci"},{"issue":"2","key":"3369_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jhep.2015.04.016","volume":"63","author":"M Chen","year":"2015","unstructured":"Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI (2015) Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol 63(2):503\u2013514","journal-title":"J Hepatol"},{"issue":"4","key":"3369_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/em.22173","volume":"59","author":"S Chen","year":"2018","unstructured":"Chen S, Ren Z, Yu D, Ning B, Guo L (2018a) DNA damage-induced apoptosis and mitogen-activated protein kinase pathway contribute to the toxicity of dronedarone in hepatic cells. Environ Mol Mutagen 59(4):278\u2013289","journal-title":"Environ Mol Mutagen"},{"issue":"6","key":"3369_CR6","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s00204-018-2196-x","volume":"92","author":"S Chen","year":"2018","unstructured":"Chen S, Wu Q, Ning B, Bryant M, Guo L (2018b) The role of hepatic cytochrome P450s in the cytotoxicity of dronedarone. Arch Toxicol 92(6):1969\u20131981","journal-title":"Arch Toxicol"},{"issue":"7","key":"3369_CR7","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00204-020-02753-y","volume":"94","author":"S Chen","year":"2020","unstructured":"Chen S, Wu Q, Li X, Li D, Fan M, Ren Z, Bryant M, Mei N, Ning B, Guo L (2020) The role of hepatic cytochrome P450s in the cytotoxicity of sertraline. Arch Toxicol 94(7):2401\u20132411","journal-title":"Arch Toxicol"},{"issue":"1","key":"3369_CR8","first-page":"68","volume":"39","author":"S Chen","year":"2021","unstructured":"Chen S, Wu Q, Li X, Li D, Mei N, Ning B, Puig M, Ren Z, Tolleson WH, Guo L (2021) Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity. J Environ Sci Health C Toxicol Carcinog 39(1):68\u201386","journal-title":"J Environ Sci Health C Toxicol Carcinog"},{"issue":"1","key":"3369_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/jmg.21.1.27","volume":"21","author":"RG Cooper","year":"1984","unstructured":"Cooper RG, Evans DA, Whibley EJ (1984) Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet 21(1):27\u201333","journal-title":"J Med Genet"},{"issue":"6","key":"3369_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/BF02455990","volume":"32","author":"RG Cooper","year":"1987","unstructured":"Cooper RG, Evans DA, Price AH (1987) Studies on the metabolism of perhexiline in man. Eur J Clin Pharmacol 32(6):569\u2013576","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"3369_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-2125.2005.02570.x","volume":"61","author":"BJ Davies","year":"2006","unstructured":"Davies BJ, Coller JK, James HM, Somogyi AA, Horowitz JD, Sallustio BC (2006) The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. Br J Clin Pharmacol 61(3):321\u2013325","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3369_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1124\/dmd.106.012252","volume":"35","author":"BJ Davies","year":"2007","unstructured":"Davies BJ, Coller JK, Somogyi AA, Milne RW, Sallustio BC (2007) CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos 35(1):128\u2013138","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"3369_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2125.2007.03015.x","volume":"65","author":"BJ Davies","year":"2008","unstructured":"Davies BJ, Herbert MK, Coller JK, Somogyi AA, Milne RW, Sallustio BC (2008) Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. Br J Clin Pharmacol 65(3):347\u2013354","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3369_CR14","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3390\/cancers14041043","volume":"14","author":"B Dhakal","year":"2022","unstructured":"Dhakal B, Li CMY, Li R, Yeo K, Wright JA, Gieniec KA, Vrbanac L, Sammour T, Lawrence M, Thomas M, Lewis M, Perry J, Worthley DL, Woods SL, Drew P, Sallustio BC, Smith E, Horowitz JD, Maddern GJ, Licari G, Fenix K (2022) The antianginal drug perhexiline displays cytotoxicity against colorectal cancer cells in vitro: a potential for drug repurposing. Cancers 14(4):1043","journal-title":"Cancers"},{"issue":"6","key":"3369_CR15","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00204-021-03060-w","volume":"95","author":"Y He","year":"2021","unstructured":"He Y, Zhu L, Ma J, Lin G (2021) Metabolism-mediated cytotoxicity and genotoxicity of pyrrolizidine alkaloids. Arch Toxicol 95(6):1917\u20131942","journal-title":"Arch Toxicol"},{"issue":"11","key":"3369_CR16","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1021\/acs.molpharmaceut.9b00361","volume":"16","author":"J Hofman","year":"2019","unstructured":"Hofman J, Sorf A, Vagiannis D, Sucha S, Kammerer S, K\u00fcpper JH, Chen S, Guo L, Ceckova M, Staud F (2019) Brivanib exhibits potential for pharmacokinetic drug-drug interactions and the modulation of multidrug resistance through the inhibition of human ABCG2 drug efflux transporter and CYP450 biotransformation enzymes. Mol Pharm 16(11):4436\u20134450","journal-title":"Mol Pharm"},{"key":"3369_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109448","volume":"340","author":"J Hofman","year":"2021","unstructured":"Hofman J, Vagiannis D, Chen S, Guo L (2021) Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance. Chem Biol Interac 340:109448","journal-title":"Chem Biol Interac"},{"issue":"2","key":"3369_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejcnurse.2006.01.001","volume":"5","author":"S Inglis","year":"2006","unstructured":"Inglis S, Stewart S (2006) Metabolic therapeutics in angina pectoris: history revisited with perhexiline. Eur J Cardiovasc Nurs 5(2):175\u2013184","journal-title":"Eur J Cardiovasc Nurs"},{"key":"3369_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105488","volume":"153","author":"KR MacKenzie","year":"2020","unstructured":"MacKenzie KR, Zhao M, Barzi M, Wang J, Bissig K-D, Maletic-Savatic M, Jung SY, Li F (2020) Metabolic profiling of norepinephrine reuptake inhibitor atomoxetine. Eur J Pharm Sci 153:105488","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"3369_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/toxsci\/kfm052","volume":"97","author":"LD Marroquin","year":"2007","unstructured":"Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y (2007) Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci 97(2):539\u2013547","journal-title":"Toxicol Sci"},{"issue":"12","key":"3369_CR21","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/jcph.1934","volume":"61","author":"MG Midei","year":"2021","unstructured":"Midei MG, Darpo B, Ayers G, Brown R, Couderc J-P, Daly W, Ferber G, Sager PT, Camm AJ (2021) Electrophysiological and ECG effects of perhexiline, a mixed cardiac ion channel inhibitor, evaluated in nonclinical assays and in healthy subjects. J Clin Pharmacol 61(12):1606\u20131617","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"3369_CR22","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1007\/s00204-021-03082-4","volume":"95","author":"A Mueller-Schoell","year":"2021","unstructured":"Mueller-Schoell A, Michelet R, Weinelt F, Kloft C, Mikus G (2021) CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications. Arch Toxicol 95(8):2867\u20132870","journal-title":"Arch Toxicol"},{"issue":"2","key":"3369_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/toxsci\/kfw173","volume":"154","author":"Z Ren","year":"2016","unstructured":"Ren Z, Chen S, Zhang J, Doshi U, Li AP, Guo L (2016) Endoplasmic reticulum stress induction and ERK1\/2 activation contribute to nefazodone-induced toxicity in hepatic cells. Toxicol Sci 154(2):368\u2013380","journal-title":"Toxicol Sci"},{"key":"3369_CR24","doi-asserted-by":"publisher","first-page":"104987","DOI":"10.1016\/j.tiv.2020.104987","volume":"34","author":"Z Ren","year":"2020","unstructured":"Ren Z, Chen S, Seo JE, Guo X, Li D, Ning B, Guo L (2020) Mitochondrial dysfunction and apoptosis underlie the hepatotoxicity of perhexiline. Toxicol in Vitro 34:104987","journal-title":"Toxicol in Vitro"},{"key":"3369_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2020.109353","volume":"334","author":"Z Ren","year":"2021","unstructured":"Ren Z, Chen S, Pak S, Guo L (2021) A mechanism of perhexiline\u2019s cytotoxicity in hepatic cells involves endoplasmic reticulum stress and p38 signaling pathway. Chem Biol Interac 334:109353","journal-title":"Chem Biol Interac"},{"issue":"2","key":"3369_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1365-2125.2002.01618.x","volume":"54","author":"BC Sallustio","year":"2002","unstructured":"Sallustio BC, Westley IS, Morris RG (2002) Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br J Clin Pharmacol 54(2):107\u2013114","journal-title":"Br J Clin Pharmacol"},{"issue":"6312","key":"3369_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/bmj.284.6312.295","volume":"284","author":"RR Shah","year":"1982","unstructured":"Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JD (1982) Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (clin Res Ed) 284(6312):295\u2013299","journal-title":"Br Med J (clin Res Ed)"},{"issue":"6","key":"3369_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1046\/j.1365-2125.2003.01805.x","volume":"55","author":"LB S\u00f8rensen","year":"2003","unstructured":"S\u00f8rensen LB, S\u00f8rensen RN, Miners JO, Somogyi AA, Grgurinovich N, Birkett DJ (2003) Polymorphic hydroxylation of perhexiline in vitro. Br J Clin Pharmacol 55(6):635\u2013638","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3369_CR29","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00204-020-02963-4","volume":"95","author":"N Todorovi\u0107 Vukoti\u0107","year":"2021","unstructured":"Todorovi\u0107 Vukoti\u0107 N, \u0110or\u0111evi\u0107 J, Peji\u0107 S, \u0110or\u0111evi\u0107 N, Pajovi\u0107 SB (2021) Antidepressants- and antipsychotics-induced hepatotoxicity. Arch Toxicol 95(3):767\u2013789","journal-title":"Arch Toxicol"},{"issue":"4","key":"3369_CR30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3390\/cancers12040813","volume":"12","author":"D Vagiannis","year":"2020","unstructured":"Vagiannis D, Novotna E, Skarka A, Kammerer S, K\u00fcpper J-H, Chen S, Guo L, Staud F, Hofman J (2020) Ensartinib (X-396) effectively modulates pharmacokinetic resistance mediated by ABCB1 and ABCG2 drug efflux transporters and CYP3A4 biotransformation enzyme. Cancers 12(4):813","journal-title":"Cancers"},{"key":"3369_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.toxlet.2016.04.016","volume":"253","author":"Q Wu","year":"2016","unstructured":"Wu Q, Ning B, Xuan J, Ren Z, Guo L, Bryant MS (2016) The role of CYP 3A4 and 1A1 in amiodarone-induced hepatocellular toxicity. Toxicol Lett 253:55\u201362","journal-title":"Toxicol Lett"},{"key":"3369_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cbi.2015.10.009","volume":"255","author":"J Xuan","year":"2016","unstructured":"Xuan J, Chen S, Ning B, Tolleson WH, Guo L (2016) Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity. Chem Biol Interact 255:63\u201373","journal-title":"Chem Biol Interact"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-022-03369-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-022-03369-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-022-03369-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T20:16:10Z","timestamp":1666296970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-022-03369-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3369"],"URL":"https:\/\/doi.org\/10.1007\/s00204-022-03369-0","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"assertion":[{"value":"24 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}